Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

l'oreal australia pty ltd - butyl methoxydibenzoylmethane, quantity: 40 mg/g; octocrylene, quantity: 35 mg/g; octyl salicylate, quantity: 50 mg/g; homosalate, quantity: 50 mg/g; bemotrizinol, quantity: 15 mg/g; ethylhexyl triazone, quantity: 25 mg/g; drometrizole trisiloxane, quantity: 10 mg/g; ecamsule, quantity: 3.3 mg/g - spray - excipient ingredients: caprylyl glycol; ethylenediamine/stearyl dimer dilinoleate copolymer; pentaerythrityl tetra-di-t-butyl hydroxyhydrocinnamate; dimeticone 5; butylated hydroxytoluene; acrylates copolymer; purified water; disodium edetate; styrene/acrylates copolymer; dicaprylyl carbonate; dl-alpha-tocopherol; peg-8 laurate; poloxamer; glycerol; diglycol/chdm/isophthalates/sip copolymer; trolamine; diisopropyl sebacate; ethanol; fragrance (perfume) - may assist in preventing some skin cancers (sunscreen) ; may reduce the risk of some skin cancers (sunscreen) ; spf 50 plus broad spectrum very high protection sunscreen ; can aid in the prevention of premature skin ageing (sunscreen) ; can aid in the prevention of solar keratosis (sunscreen) ; can aid in the prevention of sunspots (sunscreen)

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

l'oreal australia pty ltd - butyl methoxydibenzoylmethane, quantity: 30 mg/g; octyl salicylate, quantity: 50 mg/g; bemotrizinol, quantity: 30 mg/g; ethylhexyl triazone, quantity: 25 mg/g; ecamsule, quantity: 9.9 mg/g; drometrizole trisiloxane, quantity: 30 mg/g - spray - excipient ingredients: alkyl (c12-15) benzoate; diglycol/chdm/isophthalates/sip copolymer; disodium edetate; isopropyl lauroyl sarcosinate; acrylates copolymer; pentaerythrityl tetra-di-t-butyl hydroxyhydrocinnamate; trolamine; caprylyl glycol; styrene/acrylates copolymer; propylene glycol; ethanol; peg-8 laurate; glycerol; sodium dodecylbenzenesulfonate; purified water; ethylenediamine/stearyl dimer dilinoleate copolymer; dl-alpha-tocopherol - may assist in preventing some skin cancers (sunscreen) ; may reduce the risk of some skin cancers (sunscreen) ; spf 50 plus broad spectrum very high protection sunscreen ; can aid in the prevention of premature skin ageing (sunscreen) ; can aid in the prevention of solar keratosis (sunscreen) ; can aid in the prevention of sunspots (sunscreen)

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - buprenorphine, quantity: 5 mg - drug delivery system, transdermal - excipient ingredients: levulinic acid; oleyl oleate; povidone; polyethylene; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; butyl acrylate; acrylic acid; 2,2'-azobisisobutyronitrile; aluminium acetylacetonate; heptane; acrylates copolymer; ethylene distearamide; adipic acid/1,4-butanediol/mdi copolymer; pentaerythrityl tetra-di-t-butyl hydroxyhydrocinnamate - buprenorphine sandoz patches are indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. buprenorphine sandoz patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. buprenorphine sandoz patches are not indicated as an as-needed (prn) analgesia.

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - buprenorphine, quantity: 20 mg - drug delivery system, transdermal - excipient ingredients: povidone; oleyl oleate; polyethylene; levulinic acid; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; butyl acrylate; acrylic acid; 2,2'-azobisisobutyronitrile; aluminium acetylacetonate; heptane; acrylates copolymer; ethylene distearamide; adipic acid/1,4-butanediol/mdi copolymer; pentaerythrityl tetra-di-t-butyl hydroxyhydrocinnamate - buprenorphine sandoz patches are indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. buprenorphine sandoz patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. buprenorphine sandoz patches are not indicated as an as-needed (prn) analgesia.

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - buprenorphine, quantity: 15 mg - drug delivery system, transdermal - excipient ingredients: povidone; polyethylene; levulinic acid; oleyl oleate; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; butyl acrylate; acrylic acid; 2,2'-azobisisobutyronitrile; aluminium acetylacetonate; heptane; acrylates copolymer; ethylene distearamide; adipic acid/1,4-butanediol/mdi copolymer; pentaerythrityl tetra-di-t-butyl hydroxyhydrocinnamate - buprenorphine sandoz patches are indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. buprenorphine sandoz patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. buprenorphine sandoz patches are not indicated as an as-needed (prn) analgesia.

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - buprenorphine, quantity: 10 mg - drug delivery system, transdermal - excipient ingredients: povidone; polyethylene; levulinic acid; oleyl oleate; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; butyl acrylate; acrylic acid; 2,2'-azobisisobutyronitrile; aluminium acetylacetonate; heptane; acrylates copolymer; ethylene distearamide; adipic acid/1,4-butanediol/mdi copolymer; pentaerythrityl tetra-di-t-butyl hydroxyhydrocinnamate - buprenorphine sandoz patches are indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. buprenorphine sandoz patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. buprenorphine sandoz patches are not indicated as an as-needed (prn) analgesia.

Канада - Енглески - Health Canada

glaxosmithkline inc - diflucortolone valerate - cream - 0.1% - diflucortolone valerate 0.1% - anti-inflammatory agents

Канада - Енглески - Health Canada

glaxosmithkline inc - diflucortolone valerate - cream - 0.1% - diflucortolone valerate 0.1% - anti-inflammatory agents

Канада - Енглески - Health Canada

bausch health, canada inc. - desoximetasone - cream - 0.25% - desoximetasone 0.25% - anti-inflammatory agents

Канада - Енглески - Health Canada

bausch health, canada inc. - desoximetasone - cream - 0.05% - desoximetasone 0.05% - anti-inflammatory agents